Royalty Pharma plc
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.4B | $2.3B | $2.4B | $2.2B | $2.3B |
| Operating income | $1.6B | $1.3B | $1.5B | $307.1M | $1.4B |
| Cash from operations | $2.5B | $2.8B | $3.0B | $2.1B | $2.0B |
| Share repurchases | $1.2B | $229.7M | $304.8M | $0 | $0 |
| Impairments | — | $0 | $0 | $615.8M | $0 |
| Total assets | $19.6B | $18.2B | $16.4B | $16.8B | $17.5B |
| Total liabilities | $9.9B | $7.9B | $6.3B | $7.3B | $7.3B |
Shares outstanding 575.8M · Free float 91.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.